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In a placebo-controlled randomised study of the platelet-derived growth factor receptor (PDGFR) inhibitor imatinib mesylate and
docetaxel in metastatic prostate cancer with bone metastases (n¼116), no significant differences in progression-free and overall
survival were observed. To evaluate pharmacodynamic correlates of outcomes, we assessed the association of plasma platelet-
derived growth factor (PDGF) isoform kinetics and PDGFR inhibition with progression-free and overall survival by individual
treatment arm. We found that in the docetaxel–placebo arm alone, the probability of decrease in PDGFR phosphorylation (Pr-Decr-
pPDGFR) above 0.5 (vs p0.5) was associated with a sharp increase in all measured plasma PDGF isoforms (P¼0.006 for AA, 0.002
for BB, 0.045 for AB); a decreased median progression-free survival of 3.3 months vs 6.8 months (hazard ratio (HR) 2.5; P¼0.006 in
log-rank test) and an inferior median overall survival of 20 months vs 430 months (HR 3.1; P¼0.04 in log-rank test). By contrast, in
the docetaxel plus imatinib arm, the association of Pr-Decr-pPDGFR 40.5 with a rise in plasma PDGF isoform concentrations and
inferior survival was not observed. The data suggest that dynamic changes in PDGFR phosphorylation in peripheral blood leukocytes
predict docetaxel efficacy. Rising plasma PDGF concentrations may explain and/or mark docetaxel resistance. Validation and
mechanistic studies addressing these unexpected findings should anticipate a confounding influence of concurrent PDGFR inhibitor
therapy.
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Preclinical (Uehara et al, 2003; Kim et al, 2006) and early clinical
(Mathew et al, 2004) studies suggested a benefit for the
combination of therapeutic inhibition of the platelet-derived
growth factor receptor (PDGFR) and taxane chemotherapy for
bone metastases from prostate cancer. In a randomised placebo-
controlled clinical trial of PDGFR inhibition with imatinib
mesylate (Buchdunger et al, 2000) and docetaxel chemotherapy
in men with castration-resistant prostate cancer and bone
metastases, high-frequency expression of the target – phospho-
rylated PDGFR in metastatic tumour in bone – was confirmed,
with the evidence of enhanced systemic inhibition of PDGFR
phosphorylation measured in peripheral blood leukocytes and
significant reductions in urine N-telopeptide, a bone lysis marker,
in the docetaxel plus imatinib arm compared with docetaxel plus
placebo arm. However, there was no clinical benefit, as assessed by
progression-free survival (PFS) and overall survival, to support a
definitive larger randomised study (Mathew et al, 2007).
To evaluate pharmacodynamic correlates of PDGFR inhibition
with therapeutic results, we assessed the kinetics of circulating
platelet-derived growth factor (PDGF) dimeric isoforms and
PDGFR inhibition in peripheral blood leukocytes and their
association with PFS and overall survival in the control and
imatinib-containing arms. Current knowledge indicates that the
platelet-derived growth factors (PDGFs) consist of five different
dimeric isoforms (AA, BB, AB, CC, and DD) derived from four
different polypeptide chains encoded by four different genes acting
via two receptor tyrosine kinases, PDGFR a and b (Fredriksson
et al, 2004; Reigstad et al, 2005). PDGF functions have been
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simplicated in a wide range of physiological and pathological
processes including those relevant to neoplasia such as angio-
genesis, inflammation and mesenchymal differentiation (Pietras
et al, 2003; Yu et al, 2003). Although circulating ligand kinetic
profiles have not been described in the context of PDGFR
inhibition in neoplasia, effective therapeutic inhibition of a range
of other receptor tyrosine kinases, including epidermal growth
factor receptor or the vascular endothelial growth factor receptor,
have been associated with particular variations in circulating
ligand concentrations (Burdick et al, 2000; Bocci et al, 2004;
DePrimo et al, 2007).
MATERIALS AND METHODS
Description of cohort
A total of 116 men with castration-resistant metastatic prostate
cancer were accrued from 28 April 2003 through 19 August 2005 at
five tertiary cancer care centres as described earlier (Mathew et al,
2007). Eligibility criteria included histologic evidence of adeno-
carcinoma of the prostate with radiological evidence of bone
metastases, a serum testosterone level of p50ngdl
 1, and
evidence of disease progression as manifested by either successive
increases in serum prostate-specific antigen (PSA) level, the
appearance of new lesions on bone scan, progressive bidimen-
sional disease and/or worsening malignant bone pain. All patients
provided written informed consent according to institutional
guidelines. The study was supported by Novartis Pharmaceuticals
and an Inter-Specialised Program of Research Excellence (SPORE)
grant from the National Cancer Institute.
Therapeutics
Patients were randomly assigned to receive docetaxel at 30mgm
 2
administered intravenously over 60min, on days 1, 8, 15, and 22 in
42-day cycles, along with daily oral imatinib mesylate 600mg
(DþI) or placebo (DþP). Therapy was to continue until disease
progression was established. On account of toxicity, the starting
dose of imatinib was later lowered to 400mg daily.
Samples for correlative studies
Baseline laboratory studies included an optional peripheral blood
sample for biomarker monitoring of PDGFR inhibition. Serial
peripheral blood samples for monitoring phosphorylated-PDGFR
(pPDGFR) were repeated on day 1 of cycle 2 (C2D1) prior to
docetaxel administration, in patients who consented to provide
these optional research samples. There were 88 paired samples (41
DþI, 47 DþP) for peripheral blood leukocyte PDGFR phosphor-
lation assay. There were 102 samples at baseline (50 DþIa n d5 2
DþP) for PDGF ligand assay and 89 of these (42 DþI, 47 DþP)
had a paired sample available after therapy. Correlations of pPDGFR
and plasma PDGF kinetics were feasible among 88 paired samples.
Measurement of PDGF ligands
An enzyme-linked immunosorbent assay system was used to
determine the concentration of plasma PDGF-AA, PDGF-BB, and
PDGF-AB (R&D Systems, Minneapolis, MN, USA). All measure-
ments of ligand concentration (ngml
 1) were computed averages
from duplicate assays in two different enzyme-linked immuno-
sorbent assay plates.
Assay of pPDGFR expression in peripheral blood
leukocytes
Venous blood samples were drawn at baseline and at C2D1.
Cytospin preparations of peripheral blood leukocytes were stained
with the pPDGFR-b (tyr 1021) antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) conjugated to cyanine-5 by Rockland
Immunochemical Co. (Gilbertsville, PA, USA) and examined by
confocal microscopy (Mathew et al, 2007). An example of a
baseline specimen from a patient is demonstrated in Figure 1. A
laser scanning cytometer (Compucyte Corporation, Cambridge,
MA, USA) was used to measure fluorescence intensity of 2000
individual peripheral blood leukocytes and histograms were
generated for analysis.
Statistical analysis
Paired samples of pPDGFR values from peripheral blood
leukocytes were available at baseline and on C2D1 from each
patient. Using these paired samples, we estimated the probability,
Pr(Decr-pPDGFR), that the pPDGFR levels within each patient
decreased from baseline to C2D1 and assessed the ability of the
estimated Pr(Decr-pPDGFR) values to predict PFS (Mathew et al,
2007). The large sample sizes (approximately 2000 cells each) of
cell-specific pPDGFR values obtained at both measurement points
for each patient provide highly reliable within-patient estimators
of Pr(Decr-pPDGFR). Each patient’s Pr(Decr-pPDGFR) estimator
was based on a Wilcoxon–Mann–Whitney statistic (Wilcoxon and
Wolfe, 1979). Descriptive statistical analyses were carried out using
histograms, box plots, means, and s.d. Scatter plots, non-
parametric regression using lowess smoothers (Cleveland, 1979;
Cleveland and Devlin, 1988), linear regression and Pearson’s
correlation (Neter et al, 1990) were used to assess association
between numerical variables. Wilcoxon signed-rank tests for
paired data (Hollander and Wolfe, 1979) were used to assess
ligand changes between baseline and C2D1 within treatment
groups. Wilcoxon rank-sum tests (Hollander and Wolfe, 1979)
were used to compare unpaired ligand measurements at baseline to
those on C2D1. Unadjusted survival probabilities were estimated
using the Kaplan–Meier method (Kaplan and Meier, 1958). The
two-sided log-rank test (Mantel, 1966) was used to compare PFS
between treatment groups. The Cox proportional hazards model
(Cox, 1972) was employed to evaluate the prognostic importance
of covariates. The Grambsch–Therneau test (Grambsch and
Figure 1 Phospho-PDGFR expression in peripheral blood leukocytes by
immunofluorescent antibody staining.
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sTherneau, 1994) was used to assess the proportional hazard
assumption for the Cox regression model. All P-values were
derived from two-sided tests. All computations were performed
using SPLUS 2000 (Insightful Corporation, Seattle, WA, USA). To
facilitate explanation of the results, specific regression models
involving PDGF kinetics are given below, in the Results section.
RESULTS
Plasma PDGF dimer distributions
We assessed means and s.d. of PDGF dimer values (AA, AB, and
BB) at baseline by treatment group (DþI vs DþP). The results
(Table 1) show no statistically significant differences between the
two groups.
Plasma PDGF dimer kinetics
To assess changes in plasma PDGF dimeric isoform concentrations
(AA, AB, BB, and total) after one cycle of therapy, denoting the
baseline value as X and the value on C2D1 as Y, we fit the linear
model Y¼mþa Xþ(bþg X)*[Imat]þe, where [Imat]¼1 in the
DþI group and 0 in the DþP group; a, b, and g are parameters,
and e is measurement error. Thus, the C2D1 (Y) value is assumed
to be a linear function of the baseline (X) value within each
treatment group, with average values (mþb)þ(aþg)X in the
DþI group and mþaX in the DþP group, that is, straight lines
having both different slopes and different intercepts. Thus, the
imatinib effect is the difference {(mþb)þ(aþ g)X} {mþaX}
¼bþgX, which also is a linear function of the baseline value X.
Figure 2 shows scatter plots and fitted models of C2D1 (Y) values
with baseline (X) for each PDGF dimer set. Although the C2D1
DþP values were on average higher than the DþI values, no
significant differences were noted between the treatment groups,
and C2D1 values were on average much smaller than baseline
values for each patient.
Plasma PDGF dimer kinetics and PDGFR phosphorylation
status by treatment arm
Because variations in ligand kinetics may be uniquely dependent
upon quantitative receptor inhibition, we assessed plasma PDGF
Table 1 Plasma platelet-derived growth factor (PDGF) isoform concentrations (ngml
 1) at baseline by treatment group: mean and standard deviation
(s.d.)
Docetaxel+placebo Docetaxel+imatinib
P-value
PDGF ligands N Mean s.d. N Mean s.d. (Wilcoxon signed-rank test)
AA 52 1.671 0.657 50 1.535 0.738 0.102
BB 52 0.569 0.313 50 0.496 0.346 0.267
AB 52 3.25 2.185 50 3.04 2.975 0.338
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Figure 2 Scatter plots and fitted lines of plasma PDGF kinetics for isoforms AA, AB, BB, and the sum AAþABþBB, for each treatment arm. The dotted
451 line is a reference corresponding to no differences between the cycle 2 day 1 (C2D1) and baseline (BL) values.
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sdimer kinetics in relation to variations in PDGFR phosphorylation
in the control and imatinib-containing arms. The following
piecewise linear regression model was fit to each change in dimer
value D¼Y X
D ¼ m þ e;if PrðDecr-pPDGFRÞp0:5;
¼ m þ b  ½ PrðDecr-pPDGFRÞ 0:5 
þ e;if PrðDecr-pPDGFRÞ40:5:
This model was suggested by the non-parametric smoothed plots
given in Figure 3A. For the DþP arm, all slopes (b) for values of D
where Pr(Decr-pPDGFR) 40.5 were negative, and statistically the
slopes were significantly different from 0 for each PDGF dimer set
(P¼0.006 for AA, 0.002 for BB, 0.045 for AB, and 0.009 for total
ligand). In contrast, for the DþI group (Figure 3B), the slopes (b)
were not significantly different from 0 (P¼0.334 for AA, 0.840 for
BB, 0.527 for AB, and 0.303 for total ligand).
PDGFR phosphorylation status and PFS by treatment arm
With the same cut point of Pr(Decr-pPDGFR) 40.5, at which
rising plasma PDGF concentrations were observed, PFS outcomes
were estimated. There was a large and statistically significant
difference in PFS between patients with Pr(Decr-pPDGFR) p0.5
and those with Pr(Decr-pPDGFR) 40.5 (hazard ratio (HR) is 2.5
with 95% CI: 1.3–5.1; P¼0.006 in log-rank test) in the DþP
group. The median PFS duration was 6.8 months (95% CI:
4.2–14.3) in patients with Pr(Decr-pPDGFR) p0.5 and was 3.3
months (95% CI: 2.8–5.8) in patients with Pr(Decr-pPDGFR) 40.5
(Figure 4A). In contrast, no statistically significant differences were
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Figure 3 Plasma PDGF ligand kinetics and pPDGFR dynamics in peripheral blood leukocytes by treatment arm: (A) Docetaxel and Placebo
(B) Docetaxel and Imatinib. BL=baseline; C2D1=cycle 2 day 1.
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sseen in the DþI group with a median PFS duration of 4.2 months
in both patients with Pr(Decr-pPDGFR) p0.5 and those with
Pr(Decr-pPDGFR) 40.5 (HR is 1.7 with 95% CI: 0.88–3.3;
P¼0.113 in log-rank test) (Figure 4B). The combined effects of
both Pr(Decr-pPDGFR) p0.5 and treatment on PFS, however, are
shown by the four Kaplan–Meier curves in Figure 4C, which
indicates that the advantageous effect of Pr(Decr-pPDGFR) p0.5
vs Pr(Decr-pPDGFR) 40.5 was greater than any treatment effect.
In the multivariate analysis, a Cox regression model was fit for
PFS including treatment arm assignment, an indicator of Pr(Decr-
pPDGFR) 40.5 interacting with each treatment arm, haemoglobin,
serum alkaline phosphatase, history of any prior chemotherapy
exposure, and baseline Eastern Cooperative Oncology Group
(ECOG) Performance Score. The proportional hazard assumption
was valid (P¼0.612). Independent factors predicting PFS (Table 2)
were Pr(Decr-pPDGFR) 40.5 (HR¼2.419, P¼0.015 in Placebo
group; HR¼1.998, P¼0.037 in Imatinib group), haemoglobin
X11gdl
 1 (HR¼0.300, P¼0.005), and serum alkaline phospha-
tase (HR¼1.59, P¼0.061).
PDGFR phosphorylation status and overall survival by
treatment arm
We similarly assessed the association of Pr(Decr-pPDGFR) 40.5.
with overall survival outcomes by treatment arm and found that in
the DþP group, a Pr(Decr-pPDGFR) 40.5 was associated with a
median overall survival of 20 months (95% CI: 13.7 to 30þ) vs
430 months (median, not reached) when Pr(Decr-pPDGFR) was
p0.5 (HR is 2.5 with 95% CI: 1.3–5.1; P¼0.04 in log-rank test)
(Figure 5A). There was no significant differences in overall survival
in the corresponding DþI subgroups; when the Pr(Decr-pPDGFR)
40.5, median survival was 21 months (95% CI: 19.2 to 30þ) and
when Pr(Decr-pPDGFR) was p0.5, overall survival was 22 months
(95% CI: 12.1 to 30þ) (Figure 5B). The HR for the comparison in
overall survival between these subgroups in the imatinib-contain-
ing arm was 0.96 (95% CI: 0.33–2.78; P¼0.94 in log-rank test). In
the multivariate analysis, a Cox regression model was fit for overall
survival (Table 2) including treatment arm assignment, Pr(Decr-
pPDGFR) 40.5 with treatment arm, haemoglobin, serum alkaline
phosphatase, history of any prior chemotherapy exposure, and
baseline ECOG performance score. The proportional hazard
assumption was valid (P¼0.757). The only independent factor
predicting survival was Pr(Decr-pPDGFR) 40.5 in docetaxel plus
placebo arm (HR¼3.24, P¼0.049).
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Figure 4 Progression-free survival and pPDGFR dynamics in peripheral
blood leukocytes by treatment arm: (A) Docetaxel and Placebo
(B) Docetaxel and Imatinib, and (C) all patients. Pr(Decr-pPDGFR)=
probability of decrease in phosphorylated PDGFR.
Table 2 Multivariate analysis of progression-free and overall survival
Estimate s.d. HR P-value
Progression-free survival
Imatinib therapy 0.272 0.299 1.312 0.365
Pr(Decr-pPDGFR)40.5: Imatinib 0.692 0.331 1.998 0.037
Pr(Decr-pPDGFR)40.5: Placebo 0.884 0.363 2.419 0.015
log(PDGF at C2D1) log(PDGF at BL)  0.325 0.300 0.723 0.122
Hemoglobin X11gdl
 1  1.262 0.444 0.283 0.0045
Elevated alkaline phosphatase 0.461 0.247 1.59 0.061
Prior chemotherapy 0.018 0.123 1.018 0.885
ECOG performance score¼2  0.125 0.521 0.883 0.811
Overall survival
Imatinib therapy 0.856 0.626 2.353 0.172
Pr(Decr-pPDGFR)40.5: Imatinib 0.249 0.612 1.283 0.684
Pr(Decr-pPDGFR)40.5: Placebo 1.192 0.606 3.293 0.049
log(PDGF at C2D1) log(PDGF at BL)  0.043 0.399 0.957 0.913
Hemoglobin X11gdl
 1  0.669 0.717 0.512 0.351
Elevated alkaline phosphatase 0.829 0.439 2.291 0.059
Prior chemotherapy 0.297 0.204 1.346 0.145
ECOG performance score¼2 0.625 0.739 1.868 0.398
BL¼baseline; C2D1¼cycle 2 day 1; ECOG¼Eastern Cooperative Oncology
Group; HR¼hazard ratio; PDGF¼total plasma PDGF (AA+BB+AB); Pr(Decr-
pPDGFR)¼probability of decrease in phosphorylated platelet-derived growth factor
receptor; s.d.¼standard deviation.
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sDISCUSSION
Preclinical evidence suggested that PDGF signalling contributes to
the progression of bone metastases from prostate cancer. Although
PDGFR inhibitor therapy enhanced taxane efficacy in orthotopic
models of bone metastases (Uehara et al, 2003; Kim et al, 2006),
this was not confirmed in translation to the clinic with a
randomised trial of docetaxel chemotherapy with and without
the PDGFR inhibitor, imatinib mesylate (Mathew et al, 2007). In
the study reported here, we assessed pharmacodynamic measures
of inhibition of the target receptor, pPDGFR, with survival
outcomes within the control and imatinib-containing arms of the
randomised trial. We unexpectedly found a strong association
between the probability of decrease in phosphorylation of PDGFR
in peripheral blood leukocytes and rising plasma PDGF isoform
concentrations with inferior PFS and overall survival following
docetaxel plus placebo therapy in men with castration-resistant
prostate cancer. As these plasma PDGF kinetic profiles were absent
and the association of probability of decrease in phosphorylation
in peripheral blood leukocytes with PFS and overall survival
significantly weaker in the imatinib-containing arm, a confound-
ing effect of imatinib on these associations via PDGF-dependent
or PDGF-independent mechanisms is surmised. Interestingly
however, on multivariate analysis, Pr(Decr-pPDGFR) was signifi-
cant also in predicting PFS in the imatinib-containing arm; this
observation is reinforced by the hierarchical PFS outcomes by
Pr(Decr-pPDGFR) in Figure 4C, suggesting that imatinib effects
may narrow but not eliminate completely the predictive differences
noted on the docetaxel-alone arm.
Data from this study suggest that a rise in circulating PDGF
dimers, associated with a decreased probability of PDGFR
phosphorylation in peripheral blood leukocytes relative to baseline
following docetaxel therapy, may mark and/or explain resistance
to therapy. Further, these data suggest the potential to identify,
using these biomarkers, biological subgroups, host-defined and/or
tumour-defined, marked by different PFS and overall survival
outcomes following docetaxel therapy. As decreased probability of
phosphorylated PDGFR in peripheral blood leukocytes predicts
inferior outcomes after docetaxel therapy, it may be restated
simply that an increased probability of phosphorylated PDGFR in
peripheral blood leukocytes predicts improved PFS and overall
survival outcomes.
The limitations of this study must be emphasised as these are
retrospective analyses of the predictive value of these candidate
biomarkers of therapeutic outcome. Specifically, the unexpected
association of PDGFR phosphorylation in peripheral blood
leukocytes with taxane efficacy requires prospective validation
and these studies are planned in the phase III setting where larger
sampling is feasible; for example, a sample size of 180 is required
to confirm a HR of 2.3 for PFS with Pr(Decr-pPDGFR) 40.5 with a
power of 0.82. Whether these findings will prove relevant to the
particular dose and schedule of docetaxel studied, to the particular
disease state in prostate cancer or to other taxane-responsive
neoplasms, will also require prospective verification. Given the
findings from multivariate analysis suggesting a persistent,
although weaker, predictive effect of Pr(Decr-pPDGFR) for PFS
in the imatinib-containing arm (Table 2), the effects of other novel
therapeutics with a pPDGFR inhibitory spectrum such as sunitinib
or dasatinib in combination with docetaxel, upon the predictive
effect of Pr(Decr-pPDGFR) is also of particular interest in
prospective validation studies. Validated biomarkers that predict
efficacy of docetaxel therapy in metastatic castration-resistant
prostate cancer may be useful in partitioning subgroups of patients
that could benefit from early rotation to alternative therapeutics
when a poor anticipated outcome (PFS of 3 months when Pr(Decr-
pPDGFR) 40.5) is predicted with continued docetaxel therapy.
Additional work is necessary to assess whether the activation state
of other signalling molecules, downstream or parallel to PDGFR
activation are superior predictors of docetaxel efficacy.
Further implications of these data are that a mechanistic
explanation for a link between dynamic changes in plasma PDGF
and phosphorylated PDGFR in peripheral blood leukocytes with
docetaxel efficacy would be valuable. Increasing peripheral blood
leukocyte PDGFR phosphorylation may mirror effective antivas-
cular and immunological mechanisms in the stroma or the direct
antitumor effects of docetaxel targeting microtubules. Taxanes
have been hypothesised to function as lipopolysaccharide-mimics
capable of inducing a variety of genes in macrophages such as
tumour necrosis factor-a, interferon-g, granulocyte macrophage-
colony stimulating factor, interleukin-1b and interleukin-12 which
may enhance host immune response, modulate angiogenesis or
function as direct tumoricidal agents (Chan and Yang, 2000;
Fitzpatrick and Wheeler, 2003). Although formal experimental
evidence of in vivo activation of PDGFR in peripheral blood
leukocytes by taxanes is awaited, it is plausible that PDGFR
activation among these cell populations is a marker of a taxane-
responsive immunophenotype. As rises in plasma PDGF isoforms
are identified in subgroups with an inferior progression-free
interval, this may reflect release into circulation by resistant
tumour and accompanying neoplastic vasculature and/or
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Figure 5 Overall survival and pPDGFR dynamics in peripheral blood
leukocytes by treatment arm: (A) Docetaxel and Placebo (B) Docetaxel
and Imatinib. Pr(Decr-pPDGFR)¼probability of decrease in phospho-
rylated PDGFR.
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sdecreased binding by immunomodulatory cells lacking PDGFR
activation. The pre-operative model in progressive castration-
resistant non-metastatic prostate cancer provides an experimental
platform to study such questions and narrow such hypotheses. In
this model, an association between peripheral blood leukocyte
PDGFR phosphorylation and plasma PDGF kinetics following
pre-operative docetaxel therapy with spatial and quantitative
assessment of tissue PDGF and phosphorylated PDGFR activation
in the neoplastic, vascular and stromal components of tumour
microenvironment at surgery will be studied. Correlation of these
findings with pre-operative tumour regression, PFS and overall
survival will provide refinements in mechanistic hypotheses
linking docetaxel efficacy and PDGFR phosphorylation.
In summary, the data from this study show that pharmaco-
dynamic monitoring of target inhibition and correlation with
therapy outcomes continue to be relevant considerations in clinical
trial design. In this respect, the advantages of randomised studies
are emphasised by particular observations in the control arm that
have led to a new direction of investigation pertaining to docetaxel
efficacy. A particular contrast with this predictive strategy is worth
drawing with studies of post-therapy declines in PSA or circulating
tumour cells, which similar to estrogen-receptor, HER2, and
Oncotype DX in breast cancer, are tumour-derived predictors of
therapeutic outcomes. Post-therapy pPDGFR dynamics in peri-
pheral blood leukocytes by contrast may reflect pharmacogenomic
determinants of taxane metabolism present in both normal
somatic cells as well as host-derived tumour cells.
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